ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Clinical trials and fibromyalgia"

  • Abstract Number: 46 • 2016 ACR/ARHP Annual Meeting

    Novel Composite Responder Endpoints for Fibromyalgia Therapy Assessment

    R Michael Gendreau1, Lesley Arnold2, Daniel J. Clauw3, Judith Gendreau4, Bruce Daugherty4 and Seth Lederman4, 1Gendreau Consulting LLC, Poway, CA, 2University of Cincinnati, Cincinnati, OH, 3Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI, 4Tonix Pharmaceuticals, New York, NY

    Background/Purpose: Novel composite responder definitions for fibromyalgia (FM) clinical trials have been proposed by the Outcome Measures in Rheumatology (OMERACT) FM subcommittee.  These definitions which…
  • Abstract Number: 1872 • 2012 ACR/ARHP Annual Meeting

    Quality of Reporting in Pharmacological Randomized Controlled Trials for Fibromyalgia

    Karen Yeter1, Winnie Pang2, Nasim A. Khan3 and Karina D. Torralba2, 1Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 2Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 3Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR

    Background/Purpose: Randomized controlled trials (RCTs) are considered the gold standard for assessment of healthcare interventions. Recently, there have been growing concerns about the quality of…
  • Abstract Number: 1861 • 2012 ACR/ARHP Annual Meeting

    Efficacy and Safety of Pregabalin in Japanese Patients with Fibromyalgia: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase III Trial and Open-Label Extension Study

    Hiroyoshi Ohta1, Masayuki Ohkura1, Makoto Suzuki1, Hiroshi Oka2, Chie Usui3 and Kusuki Nishioka4, 1Pfizer Japan Inc, Tokyo, Japan, 2Rheumatic Disease Center, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan, 3Department of Psychiatry, Juntendo University School of Medicine, Juntendo University Nerima Hospital, Tokyo, Japan, 4Institute of Innovative Medical Science and Education, Tokyo Medical University, Tokyo, Japan

    Background/Purpose: Fibromyalgia (FM) is a common, chronic pain disorder, however, at the time of this study there was no approved medicine for FM patients in…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences